GLOW, KLOW and Wolverine: What the New Peptide Compounding Policy Leaves Out

The new federal peptide policy has an important limit for anyone following GLOW, KLOW or the Wolverine blend: it addresses individual active ingredients, not combinations.

Condition seven of the HHS document requires a compounded product to contain “only a single Active Pharmaceutical Ingredient.” Mixing two listed peptides does not satisfy that condition—even when each appears separately in the policy. HHS policy

That leaves a gap between the announcement and some of the products already familiar to peptide buyers. To understand it, start with what those names mean.

What is in GLOW, KLOW and Wolverine?

These names describe combinations, not individual peptide molecules. Commercial listings commonly use them as follows:

• Wolverine: BPC-157 and TB-500
• GLOW: BPC-157, TB-500 and GHK-Cu
• KLOW: BPC-157, TB-500, GHK-Cu and KPV

For example, BioLongevity Labs lists GLOW as a three-peptide combination and KLOW as the same combination with KPV added. A supplier-hosted Wolverine analysis identifies its formulation as BPC-157 plus TB-500. These documents establish how the names are used commercially; they do not establish clinical benefits or regulatory authorization. GLOW and KLOW listings · Wolverine formulation document

The distinction is easy to miss. “KLOW peptide” sounds like the name of a substance. In the listings reviewed, it is shorthand for four substances packaged together.

A familiar blend name should therefore be the beginning of a product description, not a substitute for its ingredient list.

Why listing the ingredients does not cover the blend

BPC-157, TB-500 and KPV appear in the HHS policy. GHK-Cu does not.

For Wolverine, the obstacle is the single-active-ingredient condition. For GLOW and KLOW, there is an additional issue: both commonly include GHK-Cu, which falls outside the six-peptide list.

This is our application of the policy’s wording to those ingredient combinations. HHS does not name the three blends individually. Its document provides no basis for advertising them as covered by the new policy. HHS policy and Appendix A

Why HHS drew the line at one ingredient

HHS gives a practical reason: tracking outcomes.

With one active ingredient, it is easier to connect a reported benefit, adverse event or emerging safety problem to a particular substance. Multiple active ingredients make that assessment harder.

The restriction is a condition of the agency’s proposed oversight approach—not a finding that every peptide combination is ineffective or unsafe. HHS policy, condition seven

What has actually changed?

The October announcement describes an interim approach to enforcement while the government develops its formal list of substances permitted for certain pharmacy compounding.

In plain English, HHS is describing circumstances in which it does not intend to take enforcement action against qualifying compounders. That is different from approving a drug.

There is also an unresolved timing issue. As of October 29, the Federal Register notice calls the document a draft policy. The notice is scheduled for publication on October 30 and invites comments for two weeks afterward. It says the draft is not binding on HHS or the public.

Those details matter when assessing claims that the announcement immediately authorized a particular product. A headline about expanded access cannot establish that a specific formulation qualifies. Federal Register notice

Pharmacy compounding is not FDA drug approval

Compounding allows medicines to be prepared for particular patient needs. It does not turn the finished preparation into an FDA-approved drug.

FDA explains that it does not review compounded drugs for safety, effectiveness and quality before they are marketed. Compounded products also differ from FDA-approved generic medicines, which must meet the requirements of an approved drug application. FDA’s compounding explanation

For readers comparing claims about peptide access, three questions deserve separate answers: What ingredients are in the product? What policy or law covers that preparation? What evidence supports the claims being made about it?

A supplier’s ingredient list answers the first. A pharmacy’s regulatory basis addresses the second. Neither, on its own, answers the third.

This article reports on regulatory policy and commercial terminology. It does not provide dosing, administration or formulation guidance.